| Literature DB >> 25303820 |
André Coura Perez1, Guilherme Pietrucci Buzatto2, Ivan de Picole Dantas3, João Vicente Dorgam4, Fabiana Cardoso Pereira Valera5, Edwin Tamashiro5, Wilma Terezinha Anselmo Lima6.
Abstract
INTRODUCTION: In order to better understand the pathophysiology of rhinosinusitis, several attempts have been made to create the disease in an animal model. Among the studied rodents each has its advantages and disadvantages. Rabbits are considered more appropriate for studies that require surgical manipulation or invasive procedures.Entities:
Keywords: Coelhos; Polyps; Pólipos; Rabbits; Sinusite; Sinusitis
Mesh:
Year: 2014 PMID: 25303820 PMCID: PMC9444686 DOI: 10.1016/j.bjorl.2014.07.011
Source DB: PubMed Journal: Braz J Otorhinolaryngol ISSN: 1808-8686
Figure 1Flow chart of study selection.
Incidence of rhinosinusitis in the groups of the study by Hilding (1941).
| Group I: widening of natural ostium | 3 RS (+)/0 RS (−) |
| Group II: window in the medial sinus floor | 2 RS (+)/1 RS (−) |
| Group III: medial and upper window | 0 RS (+)/3 RS (−) |
| Group IV: window in the anterior recess | 0 RS (+)/3 RS (−) |
| Control | 0 RS (+)/6 RS (−) |
RS, rhinosinusitis.
Incidence of rhinosinusites in the groups of the study by Maeyama (1981).
| Group I: albumin + | RS (+) |
| Group II: albumin + | RS (−) |
RS, rhinosinusitis.
Incidence of rhinosinusitis in the groups of the study by Drettner et al. (1987).
| Group I: pneumococcus type 3 and occlusion of maxillary sinus | RS (+) |
| Group II: pneumococcus type 3, | RS (+) |
| Group III: pneumococcus type 3 without sinus occlusion | RS (−) |
| Group IV: isolated occlusion of the maxillary sinus | RS (+) |
RS, rhinosinusitis.
Incidence of rhinosinusitis in the groups of the study by Marks (1997).
| Group I: polyvinyl sponge + | 83% RS (+) |
| Group II: control (no sponge) | RS (−) |
RS, rhinosinusitis.
Incidence of rhinosinusitis in the groups of the study by Cetin et al. (2002).
| Group I: catheter 12 Fr | 8 RS (+)/1RS (−) |
| Group II: catheter 8 Fr | 5 RS (+)/4 RS (−) |
RS, rhinosinusitis; Fr., French.
Incidence of rhinosinusitis in the groups of the study by Dufour et al. (2005).
| Group I: | RS (−) |
| Group II: | RS (+) 20% |
| Group III: | RS (+) 57% |
RS, rhinosinusitis.
Incidence of rhinosinusitis in the groups of the study by Costa et al. (2007).
| Group I: bath sponge | RS (+)/intense inflammation |
| Group II: cyanoacrylate | RS (+)/moderate inflammation |
| Group III: peripheral blood | RS (+)/slight inflammation |
| Group IV: toxoids | RS (+)/slight inflammation |
| Maxillary sinuses – controls | RS (−) |
RS, rhinosinusitis.
Incidence of rhinosinusitis in the groups of the study by Liang et al. (2008).
| Group I: Merocel® | RS (+) 50% |
| Group II: Merocel® + PMA | RS (+) 60–70% |
| Control group: contralateral maxillary sinuses | RS (+) 16% |
PMA, phorbol myristate acetate.
Incidence of rhinosinusitis in the groups of the study by Sejima et al. (2010).
| Group A: control | Polyp 0% |
| Group B: sensitization (OVA) + saline solution | Polyp 0% |
| Group C: sensitization (OVA) + VGSG | Polyp 33% |
| Group D: sensitization (OVA) + PLA | Polyp 50% |
OVA, ovalbumin; VGSG, valine-glycine-serine-glutamic acid; PLA, poly-l-arginine.